Collaborative ECHO research led by Himal Suthar, MIDS and Max Aung, PhD of the University of Southern California, Los Angeles investigates the association between the concentration of per- and polyfluoroalkyl substances (PFAS) in the blood of pregnant participants with levels of bioactive lipids from three metabolic pathways. This research, titled “Cross-Sectional Associations between Prenatal Per- and Poly-Fluoroalkyl Substances and Bioactive Lipids in Three Environmental Influences on Child Health Outcomes (ECHO) Cohorts,” is published in Environmental Science and Technology.
PFAS are a large, complex group of synthetic chemicals that have been used in consumer products around the world since about the 1950s. They are found in items such as non-stick cookware, stain-resistant fabrics, and firefighting foam. People are most likely exposed to these chemicals through contaminated water or food, using products containing PFAS, or breathing air with PFAS particles.
Because PFAS break down slowly, if at all, people and animals are repeatedly exposed to them, and blood levels of some PFAS can build up over time. Scientific studies have identified multiple health effects associated with PFAS exposure. Women exposed to PFAS during pregnancy are at increased risk for adverse birth outcomes and pregnancy complications.
Changes in bioactive lipids—metabolic and inflammation pathway indicators—have been linked to PFAS exposure and adverse pregnancy outcomes. Widespread evidence of human PFAS exposure and PFAS’ association with pregnancy outcomes warranted a detailed investigation into intermediate mechanisms of PFAS toxicity to inform risk assessment and develop potential interventions.
In this study, the research team estimated associations between 50 plasma bioactive lipids and 12 serum PFAS, in pairs and as a mixture, in 414 pregnant participants from three ECHO study sites. Serum PFAS was measured using liquid chromatography and tandem mass spectrometry. Plasma bioactive lipids were measured using mass spectrometry. Associations between prenatal PFAS exposure and bioactive lipids were quantified using various statistical analyses while controlling for several factors (e.g., maternal age, gestational age at sample collection, maternal education, pre-pregnancy BMI).
When researchers looked at data from different study sites, they found that higher levels of PFAS in blood were often linked with higher levels of certain bioactive lipids. The research team also noticed differences in the distribution of bioactive lipids between individual study sites, possibly driven by variations in the genetic makeup and sociodemographic characteristics of the populations or differences in environmental exposures due to diet.
Researchers found that the similar results from analyzing mixtures of and individual PFAS chemicals indicate that specific bioactive lipids could serve as useful biomarkers of PFAS exposure.
“Findings from our present study contextualize potential clinical care approaches proposed by the National Academies of Science, Engineering, and Medicine by providing details on specific prenatal lipid metabolite and PFAS exposure associations,” Suthar said. “While the bioactive lipids measured in this study have not yet been tested as routine biomarkers in clinical settings, these findings aid in advancing the future of healthcare as additional and more complex lipid biomarkers become measurable and are tested for clinical use.”
The researchers plan to measure associations between bioactive lipids and perinatal mental health outcomes including perinatal and postpartum depression. Future studies could also look at the influence of other variables on this relationship. For example, researchers could investigate the influence of diet, which has been linked to changes in both PFAS and bioactive lipid concentrations.